Form 4: TriSalus Life Sciences CFO Acquires Shares and Holds RSUs

James Emmett Young, CFO of TriSalus Life Sciences, reports acquisition of common stock and holdings in a living trust.

Summary

• James Emmett Young, the Chief Financial Officer of TriSalus Life Sciences, reported a transaction on May 19, 2025.
• Young acquired 13,175 shares of common stock at a price of $5.18 per share.
• Following the transaction, Young directly owns 49,663 shares of common stock.
• Young also indirectly owns 30,000 shares through the Kathleen A. Young Living Trust, for which he serves as the sole trustee.
• The 13,175 granted RSUs vest immediately.

Sentiment

Score: 6

Explanation: Neutral sentiment. This is a standard regulatory filing reflecting insider trading activity. The acquisition of shares by the CFO could be interpreted as a positive sign, but it's a single transaction and doesn't necessarily indicate a major shift in the company's outlook.

Positives

• The CFO's acquisition of shares could be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. Investors often monitor these filings for insights into management's confidence in the company.

Stakeholder Impact

• The CFO's stock purchase could have a minor positive impact on shareholder sentiment.

Key Dates

Keywords

TriSalus Life Sciences, TLSI, CFO, James Emmett Young, Stock Acquisition, Form 4, Beneficial Ownership, RSUs, Kathleen A. Young Living Trust